Straits Times Index
3,341.27 -7.60 (-0.23%) Nikkei
38,837.46 -85.54 (-0.22%) Hang Seng
18,477.47 +74.47 (+0.40%) FTSE 100
8,262.75 -12.63 (-0.15%) Bitcoin USD
68,835.35 +68.97 (+0.10%) CMC Crypto 200
1,443.16 -3.99 (-0.28%)
LLY May 2024 780.000 put
| Previous close | 0.1000 |
| Open | 0.0800 |
| Bid | 0.0000 |
| Ask | 0.0100 |
| Strike | 780.00 |
| Expiry date | 2024-05-31 |
| Day's range | 0.0100 - 0.0800 |
| Contract range | N/A |
| Volume | |
| Open interest | 862 |
BenzingaEli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS, Dementia Prospect
On Monday, privately held QurAlis Corporation entered into an exclusive license agreement with Eli Lilly and Co. (NYSE:LLY). QurAlis has granted Lilly global rights to develop and commercialize QRL-204, a splice-switching antisense oligonucleotide (ASO) designed to restore UNC13A function in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Under the terms of the agreement, QurAlis granted Lilly an exclusive, worldwide license to develop an
ZacksThe Zacks Analyst Blog Highlights Eli Lilly, T-Mobile US, BHP, American International and Exelon
Eli Lilly, T-Mobile US, BHP, American International and Exelon are part of the Zacks Analyst Blog.
PR NewswireUpdated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced solid tumors and in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC). Olomorasib is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein. These data will be shared in o
